Healthcare products company West Pharmaceutical Services (NYSE: WST) will be reporting results tomorrow before market open. Here’s what investors should know.
West Pharmaceutical Services beat analysts’ revenue expectations by 1.2% last quarter, reporting revenues of $748.8 million, up 2.3% year on year. It was a softer quarter for the company, with full-year revenue guidance missing analysts’ expectations.
Is West Pharmaceutical Services a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting West Pharmaceutical Services’s revenue to decline 1.6% year on year to $684.5 million, improving from the 3% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.23 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. West Pharmaceutical Services has missed Wall Street’s revenue estimates four times over the last two years.
Looking at West Pharmaceutical Services’s peers in the life sciences tools & services segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Medpace delivered year-on-year revenue growth of 9.3%, beating analysts’ expectations by 6%, and Danaher reported flat revenue, topping estimates by 2.7%. Medpace traded down 2.1% following the results.
Read our full analysis of Medpace’s results here and Danaher’s results here.
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. We prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
